Nagpur‑based Biotech Startup ErlySign Appoints Vishal Kumar as Vice President – Business

New Delhi | January 13, 2025: ErlySign, the Nagpur‑based biotech startup developing India’s first salivary biomarker‑based screening test for early‑stage oral cancer, has announced the appointment of Vishal Kumar as Vice President – Business. The appointment comes as ErlySign prepares for its next stage of expansion and advances its mission to make early cancer detection widely accessible and affordable.

About Vishal Kumar

• Education: B.Tech from IIT Kharagpur
• Experience: Over a decade across healthcare, health‑tech, and technology sectors
• Expertise: Scaling business functions, driving organisational transformation, and forging strategic partnerships

Previously, Vishal held leadership roles at Tata 1mg, where he spearheaded the Hospital and Corporate Health & Wellness verticals, accelerating growth and forging major institutional partnerships. His work significantly strengthened healthcare delivery across diverse ecosystems.

Shubhendra Singh, CEO, ErlySign, said: “As ErlySign expands its mission of making early cancer detection accessible and affordable, strong leadership becomes essential. Vishal’s blend of operational insight, market understanding, and ability to build for scale aligns perfectly with where we’re headed.”

Vishal Kumar, Vice President – Business, ErlySign, added: “ErlySign’s mission is powerful and urgent. A simple, non‑invasive saliva test that flags cancer risk early can transform preventive healthcare. I look forward to working with the team to expand into new markets and build partnerships that accelerate early detection for millions.”

In his new role, Vishal will:

• Lead business growth and strategic partnerships
• Drive market expansion in India and globally
• Scale operations and forge high‑impact alliances
• Strengthen ErlySign’s vision of becoming a global leader in painless, affordable early cancer detection

About ErlySign
ErlySign is a biotech startup pioneering India’s first salivary biomarker‑based screening test for early‑stage oral cancer. Its mission is to make cancer detection painless, affordable, and accessible, leveraging innovation to transform preventive healthcare.